RIPK4 Is an Immune Regulating-Associated Biomarker for Ovarian Cancer and Possesses Generalization Value in Pan-Cancer.
Autorzy:
Liao C; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Shapingba District, Chongqing 400030, China. Zhao YX; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Shapingba District, Chongqing 400030, China. HanWD; Department of Pharmacy, The General Hospital of Northern Theater Command of Chinese PLA, Shenyang, 110016 Liaoning Province, China. Lai NY; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Shapingba District, Chongqing 400030, China.
Pokaż więcej
Źródło:
Journal of immunology research [J Immunol Res] 2022 Mar 09; Vol. 2022, pp. 7599098. Date of Electronic Publication: 2022 Mar 09 (Print Publication: 2022).
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
Autorzy:
Feng KC; Department of Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. Guo YL; Department of Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. Liu Y; Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. Dai HR; Department of Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. Wang Y; Department of Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. Lv HY; Department of Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. Huang JH; Department of Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. Yang QM; Department of Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. HanWD; Department of Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. .; Department of Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2017 Jan 05; Vol. 10 (1), pp. 4. Date of Electronic Publication: 2017 Jan 05.
The four-herb Chinese medicine ANBP enhances wound healing and inhibits scar formation via bidirectional regulation of transformation growth factor pathway.
Autorzy:
Hou Q; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China; Department of Internal Medicine, Chinese PLA 148th Hospital, Zibo, P. R. China. He WJ; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China; Wound Healing and Cell Biology Laboratory, the First Affiliated Hospital, Chinese PLA General Hospital, Beijing, P. R. China. Hao HJ; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Han QW; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Chen L; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Dong L; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Liu JJ; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Li X; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Zhang YJ; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Ma YZ; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. HanWD; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China. Fu XB; Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, P. R. China; Wound Healing and Cell Biology Laboratory, the First Affiliated Hospital, Chinese PLA General Hospital, Beijing, P. R. China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Dec 09; Vol. 9 (12), pp. e112274. Date of Electronic Publication: 2014 Dec 09 (Print Publication: 2014).
Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.
Autorzy:
Zhang Y; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Wang J; Department of Cadre Health Care, Naval General Hospital, Beijing 100048, China. Wang Y; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Lu XC; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Fan H; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Liu Y; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Zhang Y; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Feng KC; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Zhang WY; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Chen MX; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. Fu X; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China. HanWD; Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
